<?xml version="1.0" encoding="UTF-8"?>
<PAPER>

<BODY>
<DIV><P>
</P>
<P>[0001] PROCESS FOR OBTAINING <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.196" epochem-id="EPOCHEM:COMPOUND:1055" name="valine" comment="" chebi-id="CHEBI:27266" relevant="false">VALINE</ne> DERIVATIVES USEFUL FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND
Field of the invention
</P>
<P>5
The present invention relates to a method for obtaining intermediates useful for obtaining a pharmaceutically active compound for manufacturing a drug for the treatment of arterial hypertension or heart
</P>
<P>10 failure.
In particular, the present invention relates to a method for obtaining intermediates useful in the synthesis of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.1" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne>. 15
Background of the invention
Spanish patent ES2084801T (equivalent to European patent EP 443983) describes acyl compounds, one of them is 20 <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.2" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> of formula (I) :
</P>
<P>[0009]
EMI2.1
</P>
<P>30
Said Spanish patent describes the preparation of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.3" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> by converting a <ne type="LIGAND" id="WO2007045675.HC.ligand-names.76" epochem-id="EPOCHEM:NEW:LIGAND:580" name="phenyl" comment="" chebi-id="CHEBI:30396" relevant="false">phenyl</ne> substituent (Zi) into <ne type="LIGAND" id="WO2007045675.HC.ligand-names.69" epochem-id="EPOCHEM:NEW:LIGAND:511" name="tetrazole" comment="" chebi-id="CHEBI:35598" relevant="false">tetrazole</ne>, where Zi is a group convertible into <ne type="LIGAND" id="WO2007045675.HC.ligand-names.70" epochem-id="EPOCHEM:NEW:LIGAND:511" name="tetrazole" comment="" chebi-id="CHEBI:35598" relevant="false">tetrazole</ne>. The examples of said patent describe the specific case in
</P>
<P>35 which Zi is a cyano group or a protected <ne type="LIGAND" id="WO2007045675.HC.ligand-names.71" epochem-id="EPOCHEM:NEW:LIGAND:511" name="tetrazole" comment="" chebi-id="CHEBI:35598" relevant="false">tetrazole</ne> ring. This is followed by final deprotection of the <ne id="WO2007045675.HC.class-names.16" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne> group, where R is preferably <ne type="LIGAND" id="WO2007045675.HC.ligand-names.2" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> or <ne type="LIGAND" id="WO2007045675.HC.ligand-names.29" epochem-id="EPOCHEM:NEW:LIGAND:503" name="benzyl" comment="" chebi-id="CHEBI:22744" relevant="false">benzyl</ne> and, if this is the case, of the <ne type="LIGAND" id="WO2007045675.HC.ligand-names.72" epochem-id="EPOCHEM:NEW:LIGAND:511" name="tetrazole" comment="" chebi-id="CHEBI:35598" relevant="false">tetrazole</ne> ring protecting group, preferably a <ne type="LIGAND" id="WO2007045675.HC.ligand-names.14" epochem-id="EPOCHEM:NEW:LIGAND:371" name="trityl" comment="" chebi-id="WO2007045675:353235" relevant="false">trityl</ne> group.
</P>
<P>[0013]
EMI3.1
This patent leaves aspects to be improved, such as the use of <ne id="WO2007045675.HC.class-names.95" epochem-id="EPOCHEM:NEW:CLASS:1058" name="azide" comment="" chebi-id="CHEBI:40910" relevant="false" type="CLASS">azide</ne> in the last synthesis steps, with the attendant risk of explosions if <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.152" epochem-id="EPOCHEM:NEW:COMPOUND:783" name="sodium azide" comment="" chebi-id="WO2007045675:830012" relevant="false">sodium azide</ne> is used, or environmental problems if <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.154" epochem-id="EPOCHEM:NEW:COMPOUND:784" name="tributyl tin azide" comment="" chebi-id="WO2007045675:641943" relevant="false">tributyl tin azide</ne> is used.
Another negative aspect lies in the use of bulky protective groups both for the <ne type="LIGAND" id="WO2007045675.HC.ligand-names.73" epochem-id="EPOCHEM:NEW:LIGAND:511" name="tetrazole" comment="" chebi-id="CHEBI:35598" relevant="false">tetrazole</ne> ring (<ne type="LIGAND" id="WO2007045675.HC.ligand-names.15" epochem-id="EPOCHEM:NEW:LIGAND:371" name="trityl" comment="" chebi-id="WO2007045675:353235" relevant="false">trityl</ne> group) and the <ne id="WO2007045675.HC.class-names.17" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne> of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.197" epochem-id="EPOCHEM:COMPOUND:1055" name="valine" comment="" chebi-id="CHEBI:27266" relevant="false">valine</ne> moiety (<ne type="LIGAND" id="WO2007045675.HC.ligand-names.27" epochem-id="EPOCHEM:NEW:LIGAND:502" name="benzylgroup" comment="" chebi-id="WO2007045675:794555" relevant="false">benzyl group</ne>) , which very considerably increase the molecular weight of the last synthesis intermediate. This molecular weight is drastically reduced in the final hydrolysis to give <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.4" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne>, thus resulting in a process of low atomic efficiency. This further creates a considerable amount of residues and increases the number of synthesis steps in the process.
Patents DE4313747, DE4407488, US5596006, EP594022 and WO9609301 describe the synthesis of sartans by formation of the biphenyl system by reacting an <ne id="WO2007045675.HC.class-names.41" epochem-id="EPOCHEM:NEW:CLASS:383" name="aryl halide" comment="" chebi-id="WO2007045675:391354" relevant="false" type="CLASS">aryl halide</ne> with <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.260" epochem-id="EPOCHEM:NEW:COMPOUND:1375" name="2- (lH-tetrazol-5-yl) phenylboronic acid" comment="2- (1H-tetrazol-5-yl) phenylboronic acid" chebi-id="WO2007045675:286599" relevant="false">2- (lH-tetrazol-5-yl) phenylboronic acid</ne> in the presence of a <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.127" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> catalyst.
European patent application EP1533305 describes a method for obtaining <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.5" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> by means of reductive amination reaction of a <ne id="WO2007045675.HC.class-names.96" epochem-id="EPOCHEM:NEW:CLASS:1059" name="biphenyl aldehyde" comment="" chebi-id="WO2007045675:850292" relevant="false" type="CLASS">biphenyl aldehyde</ne> with protected <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.156" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-valine</ne> with a <ne type="LIGAND" id="WO2007045675.HC.ligand-names.28" epochem-id="EPOCHEM:NEW:LIGAND:502" name="benzylgroup" comment="" chebi-id="WO2007045675:794555" relevant="false">benzyl group</ne> which has to be eliminated. The <ne type="LIGAND" id="WO2007045675.HC.ligand-names.32" epochem-id="EPOCHEM:NEW:LIGAND:504" name="tetrazole group" comment="" chebi-id="WO2007045675:401962" relevant="false">tetrazole group</ne> is formed in the penultimate step of the synthesis.
International patent application WO2004/026847 describes a similar process in which reductive amination of a <ne id="WO2007045675.HC.class-names.97" epochem-id="EPOCHEM:NEW:CLASS:1059" name="biphenyl aldehyde" comment="" chebi-id="WO2007045675:850292" relevant="false" type="CLASS">biphenyl aldehyde</ne> takes place, in which the <ne type="LIGAND" id="WO2007045675.HC.ligand-names.33" epochem-id="EPOCHEM:NEW:LIGAND:504" name="tetrazole group" comment="" chebi-id="WO2007045675:401962" relevant="false">tetrazole group</ne> is previously formed and protected, with protected <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.157" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> in the <ne id="WO2007045675.HC.class-names.18" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne> function.
There therefore still remains a need for a process for obtaining <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.6" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> that is safe, ecological and with high yields and few synthesis steps and from simple and commercially available starting products. Additionally, it must be possible to apply the process on an industrial scale and to avoid racemisation and the consequent separation of enantiomers.
Patent application ES200400949, incorporated herein in its entirety as reference, describes a process for the synthesis of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.7" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> that includes reaction of the intermediate (II) with a <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.261" epochem-id="EPOCHEM:COMPOUND:7221" name="boronic acid" comment="" chebi-id="CHEBI:38267" relevant="false">boronic acid</ne> of formula (III) in order to give <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.8" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> (I) :
</P>
<P>[0021]
EMI4.1
Preparation of the intermediate (II), in accordance with patent application ES200400949, comprises: a) alkylation of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.158" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> (IV) with a <ne id="WO2007045675.HC.class-names.99" epochem-id="EPOCHEM:NEW:CLASS:254" name="halide" comment="" chebi-id="CHEBI:16042" relevant="false" type="CLASS">halide</ne> of formula (V) to give a compound of formula (VI) followed by b) acylation with <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.64" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne>.
ESQUEMA I
</P>
<P>[0024]
EMI5.1
</P>
<P>[0025]
EMI5.2
In the alkylation step the <ne id="WO2007045675.HC.class-names.19" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne> must be protected in the form of <ne id="WO2007045675.HC.class-names.100" epochem-id="EPOCHEM:NEW:CLASS:1060" name="silyl ester" comment="" chebi-id="WO2007045675:550833" relevant="false" type="CLASS">silyl ester</ne> to prevent the formation of the <ne id="WO2007045675.HC.class-names.70" epochem-id="EPOCHEM:NEW:CLASS:803" name="benzyl ester" comment="" chebi-id="WO2007045675:223281" relevant="false" type="CLASS">benzyl ester</ne>. Furthermore, the dialkylation compound in the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.263" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne> of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.159" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> is inevitably formed in variable proportions and is difficult to eliminate.
In the acylation step of intermediate (VI), moreover, the reaction conditions are critical, and a restricted range of reaction parameters has to be used in order to prevent partial racemisation of compound (II) that would involve additional purifications.
This process presents disadvantages that hinder its application on an industrial scale and that are susceptible of improvement in order to reduce costs, generate less waste and improve the yield of the synthesis, as well as allow the utilisation of more easily handled reagents.
Description of the invention
A first aspect of the present invention is to provide an industrially viable process for obtaining the synthesis intermediate (II), useful in the preparation of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.9" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne>, and permitting it to be obtained with high yields and without racemisation .
A second aspect of the invention is to provide a method for obtaining the synthesis intermediate (II) with few synthesis steps.
Definitions
The term "work up" is taken to mean the work of isolation and/or purification that is carried out once the reaction has finished. This involves, for example, extractions or precipitations in an aqueous medium.
The term "one pot" is taken to mean a series of consecutive reactions that are carried out without isolating the respective intermediates.
Detailed description of the invention
The object of the present invention is to provide a new process for obtaining the intermediate of formula
(II), that permits it to be obtained with good yields, without racemisation, free from impurities and without problematic safety and environmental aspects.
Advantageously, with the process according to the first and second aspects of the invention the intermediate of formula (II) is provided free from impurities, unlike the processes described in the state of the art prior to this application.
The process for obtaining the intermediate of formula (II), useful for the synthesis of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.10" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne>,
</P>
<P>[0040]
EMI7.1
in accordance with the first aspect of the invention, is characterised in that it comprises the following steps:
a) Imination of the <ne id="WO2007045675.HC.class-names.68" epochem-id="EPOCHEM:NEW:CLASS:392" name="aldehyde" comment="" chebi-id="CHEBI:17478" relevant="false" type="CLASS">aldehyde</ne> group of a compound of formula (VII) by salts of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.160" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> (IV) with organic or <ne type="ONT" id="WO2007045675.HC.class-names.105" epochem-id="EPOCHEM:NEW:CLASS:1062" name="inorganic bases" comment="" chebi-id="WO2007045675:320986" relevant="false">inorganic bases</ne> and a <ne type="ONT" id="WO2007045675.HC.class-names.75" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.104" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>:
</P>
<P>[0043]
EMI7.2
where :
X means <ne id="WO2007045675.HC.class-names.91" epochem-id="EPOCHEM:NEW:CLASS:132" name="halogen" comment="" chebi-id="CHEBI:24473" relevant="false" type="CLASS">halogen</ne> or an -<ne type="FORMULA" id="WO2007045675.HC.formula-names.28" epochem-id="EPOCHEM:NEW:FORMULA:242" name="OSO2R" comment="" chebi-id="WO2007045675:876359" relevant="false">OSO2R</ne> group, where R is <ne type="FORMULA" id="WO2007045675.HC.formula-names.10" epochem-id="EPOCHEM:NEW:FORMULA:42" name="CF3" comment="" chebi-id="WO2007045675:424416" relevant="false">CF3</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.23" epochem-id="EPOCHEM:NEW:LIGAND:373" name="tolyl" comment="" chebi-id="WO2007045675:17853" relevant="false">tolyl</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.3" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> or <ne type="FORMULA" id="WO2007045675.HC.formula-names.14" epochem-id="EPOCHEM:NEW:FORMULA:22" name="F" comment="" chebi-id="CHEBI:29997,CHEBI:24061,CHEBI:17295" relevant="false">F</ne>; to give a compound of <ne id="WO2007045675.HC.class-names.85" epochem-id="EPOCHEM:NEW:CLASS:1020" name="imine" comment="" chebi-id="CHEBI:24783" relevant="false" type="CLASS">imine</ne> type or <ne type="ONT" id="WO2007045675.HC.class-names.13" epochem-id="EPOCHEM:NEW:CLASS:163" name="Schiff base" comment="" chebi-id="WO2007045675:664871" relevant="false">Schiff base</ne> of formula (VIII) :
</P>
<P>[0045]
EMI8.1
where :
X has the meaning defined above and B&lt;+&gt; is the protonated form of an <ne type="ONT" id="WO2007045675.HC.class-names.119" epochem-id="EPOCHEM:NEW:CLASS:1064" name="organic base" comment="" chebi-id="WO2007045675:926339" relevant="false">organic base</ne> or an alkaline cation.
b) Reduction of the <ne type="LIGAND" id="WO2007045675.HC.ligand-names.34" epochem-id="EPOCHEM:NEW:LIGAND:505" name="imine group" comment="should be &quot;imino group&quot;" chebi-id="CHEBI:29342" relevant="false">imine group</ne> of the compound of formula (VIII) followed by acidification, to give the compound of formula (VI) :
</P>
<P>[0049]
EMI8.2
c) N-Acylation of the compound of formula (VI) with <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.65" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne> to give the compound of formula
</P>
<P>[0051]
EMI8.3
Advantageously, the process according to the invention does not use protective groups of the <ne id="WO2007045675.HC.class-names.20" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne> group of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.203" epochem-id="EPOCHEM:COMPOUND:1055" name="valine" comment="" chebi-id="CHEBI:27266" relevant="false">valine</ne> moiety in preparation of the synthesis intermediate (VI). This is advantageous for what is understood as the atomic efficiency of the process, i.e. the proportion of atoms of the respective starting reagents that are incorporated into the desired product is optimum, and this translates into a considerable reduction of the amount of residues to be treated.
Schema II below shows the complete sequence of steps :
ESQUEMA II
</P>
<P>[0055]
EMI9.1
</P>
<P>[0056]
EMI9.2
</P>
<P>[0057]
EMI9.3
II In accordance with step a) , according to the first aspect of the invention, the intermediate of formula (VIII) is obtained:
</P>
<P>[0059]
EMI10.1
where X means <ne id="WO2007045675.HC.class-names.92" epochem-id="EPOCHEM:NEW:CLASS:132" name="halogen" comment="" chebi-id="CHEBI:24473" relevant="false" type="CLASS">halogen</ne> or an -<ne type="FORMULA" id="WO2007045675.HC.formula-names.29" epochem-id="EPOCHEM:NEW:FORMULA:242" name="OSO2R" comment="" chebi-id="WO2007045675:876359" relevant="false">OSO2R</ne> group, where R is <ne type="FORMULA" id="WO2007045675.HC.formula-names.11" epochem-id="EPOCHEM:NEW:FORMULA:42" name="CF3" comment="" chebi-id="WO2007045675:424416" relevant="false">CF3</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.24" epochem-id="EPOCHEM:NEW:LIGAND:373" name="tolyl" comment="" chebi-id="WO2007045675:17853" relevant="false">tolyl</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.4" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> or <ne type="FORMULA" id="WO2007045675.HC.formula-names.15" epochem-id="EPOCHEM:NEW:FORMULA:22" name="F" comment="" chebi-id="CHEBI:29997,CHEBI:24061,CHEBI:17295" relevant="false">F</ne>, and B&lt;+&gt; is the protonated form of an <ne type="ONT" id="WO2007045675.HC.class-names.120" epochem-id="EPOCHEM:NEW:CLASS:1064" name="organic base" comment="" chebi-id="WO2007045675:926339" relevant="false">organic base</ne> or an alkaline cation, by means of an imination reaction of a benzaldehyde substituted in the position for (VII) by salts of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.161" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> with organic or <ne type="ONT" id="WO2007045675.HC.class-names.118" epochem-id="EPOCHEM:NEW:CLASS:1062" name="inorganic bases" comment="" chebi-id="WO2007045675:320986" relevant="false">inorganic bases</ne>.
The <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.162" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> is mixed with the <ne id="WO2007045675.HC.class-names.42" epochem-id="EPOCHEM:NEW:CLASS:384" name="4-substituted benzaldehyde" comment="" chebi-id="WO2007045675:288448" relevant="false" type="CLASS">4-substituted benzaldehyde</ne> (VII) in the presence of an organic or <ne type="ONT" id="WO2007045675.HC.class-names.107" epochem-id="EPOCHEM:NEW:CLASS:550" name="inorganic base" comment="" chebi-id="WO2007045675:658098" relevant="false">inorganic base</ne> in equimolar proportion in relation to the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.163" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> and a <ne type="ONT" id="WO2007045675.HC.class-names.76" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.105" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> at a temperature between 0&lt;0&gt;C and the boiling temperature of the solvent, preferably between 10&lt;0&gt;C and 35[deg.]C.
A <ne type="ONT" id="WO2007045675.HC.class-names.56" epochem-id="EPOCHEM:NEW:CLASS:389" name="substituted amine-type organic base" comment="" chebi-id="WO2007045675:582643" relevant="false">substituted amine-type organic base</ne> may be used, such as <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.268" epochem-id="EPOCHEM:COMPOUND:4239" name="triethylamine" comment="" chebi-id="CHEBI:35026" relevant="false">triethylamine</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.269" epochem-id="EPOCHEM:NEW:COMPOUND:1376" name="trialkylamine" comment="" chebi-id="WO2007045675:675537" relevant="false">trialkylamine</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.270" epochem-id="EPOCHEM:NEW:COMPOUND:1377" name="diisopropylethylamine" comment="" chebi-id="WO2007045675:142410" relevant="false">diisopropylethylamine</ne> (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.271" epochem-id="EPOCHEM:NEW:COMPOUND:1378" name="DIPEA" comment="" chebi-id="WO2007045675:440737" relevant="false">DIPEA</ne>) or a <ne id="WO2007045675.HC.class-names.50" epochem-id="EPOCHEM:NEW:CLASS:386" name="metallic alcoxide" comment="" chebi-id="WO2007045675:925044" relevant="false" type="CLASS">metallic alcoxide</ne> or <ne id="WO2007045675.HC.class-names.51" epochem-id="EPOCHEM:NEW:CLASS:387" name="hydroxide" comment="" chebi-id="CHEBI:16234" relevant="false" type="CLASS">hydroxide</ne> to form a salt of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.164" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> with an <ne id="WO2007045675.HC.class-names.53" epochem-id="EPOCHEM:NEW:CLASS:388" name="alkaline metal" comment="" chebi-id="WO2007045675:764631" relevant="false" type="CLASS">alkaline metal</ne>.
The salt of an <ne id="WO2007045675.HC.class-names.54" epochem-id="EPOCHEM:NEW:CLASS:388" name="alkaline metal" comment="" chebi-id="WO2007045675:764631" relevant="false" type="CLASS">alkaline metal</ne> of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.165" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> can be prepared in situ in the reaction medium by the addition of <ne type="ONT" id="WO2007045675.HC.class-names.103" epochem-id="EPOCHEM:NEW:CLASS:1061" name="bases" comment="" chebi-id="CHEBI:22695" relevant="false">bases</ne> such as <ne id="WO2007045675.HC.class-names.24" epochem-id="EPOCHEM:NEW:CLASS:164" name="hydroxides" comment="" chebi-id="CHEBI:24651" relevant="false" type="CLASS">hydroxides</ne> and <ne id="WO2007045675.HC.class-names.25" epochem-id="EPOCHEM:NEW:CLASS:165" name="alcoxylates" comment="" chebi-id="WO2007045675:318991" relevant="false" type="CLASS">alcoxylates</ne>, for example <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.240" epochem-id="EPOCHEM:COMPOUND:7174" name="sodium hydroxide" comment="" chebi-id="CHEBI:32145" relevant="false">sodium hydroxide</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.239" epochem-id="EPOCHEM:COMPOUND:7172" name="potassium hydroxide" comment="" chebi-id="CHEBI:32035" relevant="false">potassium hydroxide</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.238" epochem-id="EPOCHEM:NEW:COMPOUND:788" name="sodium methylate" comment="" chebi-id="WO2007045675:120548" relevant="false">sodium methylate</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.241" epochem-id="EPOCHEM:NEW:COMPOUND:789" name="sodium ethylate" comment="" chebi-id="WO2007045675:981892" relevant="false">sodium ethylate</ne> in a solution in <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.243" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> and optionally <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.106" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>. The <ne id="WO2007045675.HC.class-names.126" epochem-id="EPOCHEM:NEW:CLASS:1065" name="sodium salt" comment="" chebi-id="CHEBI:26714" relevant="false" type="CLASS">sodium salt</ne> can also be prepared independently by addition of a metal in elemental state, such as <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.242" epochem-id="EPOCHEM:NEW:COMPOUND:790" name="metallic sodium" comment="" chebi-id="WO2007045675:49135" relevant="false">metallic sodium</ne>, to a solution of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.166" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> in a <ne type="ONT" id="WO2007045675.HC.class-names.77" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne> in the absence of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.107" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>, such as anhydrous <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.244" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> .
The solvent of the reaction can be selected between <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.108" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> or a protic <ne type="ONT" id="WO2007045675.HC.class-names.78" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne>. Preferably, the protic <ne type="ONT" id="WO2007045675.HC.class-names.79" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne> is an <ne id="WO2007045675.HC.class-names.26" epochem-id="EPOCHEM:NEW:CLASS:100" name="alcohol" comment="" chebi-id="CHEBI:30879" relevant="false" type="CLASS">alcohol</ne>, such as <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.245" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.100" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.149" epochem-id="EPOCHEM:NEW:COMPOUND:782" name="2-propanol" comment="" chebi-id="CHEBI:17824" relevant="false">2-propanol</ne>, but more preferably <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.246" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne>.
Alternatively, in order to encourage formation of the <ne id="WO2007045675.HC.class-names.86" epochem-id="EPOCHEM:NEW:CLASS:1020" name="imine" comment="" chebi-id="CHEBI:24783" relevant="false" type="CLASS">imine</ne> compound of formula (VIII), methods can be used to remove the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.109" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> from the medium, such as by using molecular sieves or azeotropic distillation, in which case a <ne type="ONT" id="WO2007045675.HC.class-names.80" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne> will be used during the reaction for obtaining (VIII) .
It is possible to isolate the <ne id="WO2007045675.HC.class-names.87" epochem-id="EPOCHEM:NEW:CLASS:1020" name="imine" comment="" chebi-id="CHEBI:24783" relevant="false" type="CLASS">imine</ne> or <ne type="ONT" id="WO2007045675.HC.class-names.14" epochem-id="EPOCHEM:NEW:CLASS:163" name="Schiff base" comment="" chebi-id="WO2007045675:664871" relevant="false">Schiff base</ne> (VIII) by evaporating the solvent.
Below, in accordance with step b) according to the first aspect of the invention, the intermediate (VIII) is submitted to reductive conditions to obtain the compound (VI) .
</P>
<P>[0068]
EMI11.1
Preferably, the reaction takes place in an alcoholic medium using borohydride as <ne type="ONT" id="WO2007045675.HC.class-names.11" epochem-id="EPOCHEM:NEW:CLASS:162" name="reducing agent" comment="" chebi-id="WO2007045675:343501" relevant="false">reducing agent</ne>, such as <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.144" epochem-id="EPOCHEM:NEW:COMPOUND:781" name="sodium borohydride" comment="" chebi-id="WO2007045675:460406" relevant="false">sodium borohydride</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.140" epochem-id="EPOCHEM:NEW:COMPOUND:779" name="lithium borohydride" comment="" chebi-id="WO2007045675:335475" relevant="false">lithium borohydride</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.142" epochem-id="EPOCHEM:NEW:COMPOUND:780" name="calcium borohydride" comment="" chebi-id="WO2007045675:504211" relevant="false">calcium borohydride</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.138" epochem-id="EPOCHEM:NEW:COMPOUND:778" name="sodium cyanoborohydride" comment="" chebi-id="WO2007045675:471961" relevant="false">sodium cyanoborohydride</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.136" epochem-id="EPOCHEM:NEW:COMPOUND:534" name="sodium triacetoxyborohydride" comment="" chebi-id="WO2007045675:248154" relevant="false">sodium triacetoxyborohydride</ne> .
As an alternative, the reduction can also be carried out by means of catalytic hydrogenation in the presence of hydrogen and of a <ne type="ONT" id="WO2007045675.HC.class-names.57" epochem-id="EPOCHEM:NEW:CLASS:390" name="metallic catalyst" comment="" chebi-id="WO2007045675:926372" relevant="false">metallic catalyst</ne> at atmospheric pressure, or by transfer of hydrogen in the presence of a <ne type="ONT" id="WO2007045675.HC.class-names.58" epochem-id="EPOCHEM:NEW:CLASS:390" name="metallic catalyst" comment="" chebi-id="WO2007045675:926372" relevant="false">metallic catalyst</ne> and a <ne type="ONT" id="WO2007045675.HC.class-names.63" epochem-id="EPOCHEM:NEW:CLASS:391" name="hydrogen donor" comment="" chebi-id="CHEBI:17499" relevant="false">hydrogen donor</ne> such as <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.147" epochem-id="EPOCHEM:COMPOUND:601" name="formic acid" comment="" chebi-id="CHEBI:30751" relevant="false">formic acid</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.150" epochem-id="EPOCHEM:NEW:COMPOUND:782" name="2-propanol" comment="" chebi-id="CHEBI:17824" relevant="false">2-propanol</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.101" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>, etc. The <ne type="ONT" id="WO2007045675.HC.class-names.59" epochem-id="EPOCHEM:NEW:CLASS:390" name="metallic catalyst" comment="" chebi-id="WO2007045675:926372" relevant="false">metallic catalyst</ne> used can be <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.125" epochem-id="EPOCHEM:NEW:COMPOUND:777" name="Raney-Nickel" comment="" chebi-id="WO2007045675:97041" relevant="false">Raney-Nickel</ne> or a <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.128" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.132" epochem-id="EPOCHEM:COMPOUND:7460" name="rhodium" comment="" chebi-id="CHEBI:33359" relevant="false">rhodium</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.134" epochem-id="EPOCHEM:COMPOUND:7457" name="ruthenium" comment="" chebi-id="CHEBI:30682" relevant="false">ruthenium</ne> catalyst, preferably a <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.129" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne> catalyst.
Preferably, the reduction is carried out with <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.145" epochem-id="EPOCHEM:NEW:COMPOUND:781" name="sodium borohydride" comment="" chebi-id="WO2007045675:460406" relevant="false">sodium borohydride</ne>. Under these <ne id="WO2007045675.HC.class-names.88" epochem-id="EPOCHEM:NEW:CLASS:1020" name="imine" comment="" chebi-id="CHEBI:24783" relevant="false" type="CLASS">imine</ne> bond reduction conditions, surprisingly, racemisation of the chiral centre present in the molecule is prevented. This is an additional advantage over methods that involve the utilisation of carboxylic group protective groups, since the deprotection conditions can lead to racemisation.
This process has the advantage that it does not require protection of the <ne type="LIGAND" id="WO2007045675.HC.ligand-names.1" epochem-id="EPOCHEM:NEW:LIGAND:112" name="carboxyl" comment="" chebi-id="WO2007045675:755296" relevant="false">carboxyl</ne> group of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.167" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne>.
The reductive amination reaction has the additional advantage of preventing formation of the dialkylation product .
Next, and in accordance with step c) , the compound (VI) obtained is made to react with <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.66" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne> in order to provide the intermediate (II) :
EMI13.1
where X means <ne id="WO2007045675.HC.class-names.93" epochem-id="EPOCHEM:NEW:CLASS:132" name="halogen" comment="" chebi-id="CHEBI:24473" relevant="false" type="CLASS">halogen</ne> or an -<ne type="FORMULA" id="WO2007045675.HC.formula-names.30" epochem-id="EPOCHEM:NEW:FORMULA:242" name="OSO2R" comment="" chebi-id="WO2007045675:876359" relevant="false">OSO2R</ne> group, where R is <ne type="FORMULA" id="WO2007045675.HC.formula-names.12" epochem-id="EPOCHEM:NEW:FORMULA:42" name="CF3" comment="" chebi-id="WO2007045675:424416" relevant="false">CF3</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.25" epochem-id="EPOCHEM:NEW:LIGAND:373" name="tolyl" comment="" chebi-id="WO2007045675:17853" relevant="false">tolyl</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.5" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> or <ne type="FORMULA" id="WO2007045675.HC.formula-names.16" epochem-id="EPOCHEM:NEW:FORMULA:22" name="F" comment="" chebi-id="CHEBI:29997,CHEBI:24061,CHEBI:17295" relevant="false">F</ne>.
This step c) of the process is characterised in that it consists in N-acylation of the compound of formula (VI) with <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.67" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne>, without the protection of <ne id="WO2007045675.HC.class-names.21" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne>:
</P>
<P>[0076]
EMI13.2
in the presence of an <ne type="ONT" id="WO2007045675.HC.class-names.127" epochem-id="EPOCHEM:NEW:CLASS:1066" name="aprotic organic solvent" comment="" chebi-id="WO2007045675:491390" relevant="false">aprotic organic solvent</ne> and an organic or <ne type="ONT" id="WO2007045675.HC.class-names.108" epochem-id="EPOCHEM:NEW:CLASS:550" name="inorganic base" comment="" chebi-id="WO2007045675:658098" relevant="false">inorganic base</ne> and at a temperature between -20 and 40&lt;0&gt;C, to give the compound of formula (II) :
</P>
<P>[0078]
EMI13.3
Preferably, said <ne type="ONT" id="WO2007045675.HC.class-names.128" epochem-id="EPOCHEM:NEW:CLASS:1066" name="aprotic organic solvent" comment="" chebi-id="WO2007045675:491390" relevant="false">aprotic organic solvent</ne> is selected from <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.119" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.249" epochem-id="EPOCHEM:NEW:COMPOUND:791" name="THF" comment="" chebi-id="WO2007045675:52513" relevant="false">THF</ne>) , <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.117" epochem-id="EPOCHEM:NEW:COMPOUND:775" name="dimethoxyethane" comment="" chebi-id="WO2007045675:611049" relevant="false">dimethoxyethane</ne> (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.255" epochem-id="EPOCHEM:NEW:COMPOUND:792" name="DME" comment="" chebi-id="CHEBI:42263" relevant="false">DME</ne>) and <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.123" epochem-id="EPOCHEM:NEW:COMPOUND:776" name="acetonitrile" comment="" chebi-id="CHEBI:38472" relevant="false">acetonitrile</ne> . More preferably still, it is <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.120" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.250" epochem-id="EPOCHEM:NEW:COMPOUND:791" name="THF" comment="" chebi-id="WO2007045675:52513" relevant="false">THF</ne>) .
Preferably, an <ne type="ONT" id="WO2007045675.HC.class-names.122" epochem-id="EPOCHEM:NEW:CLASS:1064" name="organic base" comment="" chebi-id="WO2007045675:926339" relevant="false">organic base</ne> will be selected from a <ne id="WO2007045675.HC.class-names.71" epochem-id="EPOCHEM:NEW:CLASS:804" name="heterocyclic compound" comment="" chebi-id="CHEBI:5686" relevant="false" type="CLASS">heterocyclic compound</ne> that contains one or more atoms of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.264" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne>. Preferably, said <ne id="WO2007045675.HC.class-names.72" epochem-id="EPOCHEM:NEW:CLASS:804" name="heterocyclic compound" comment="" chebi-id="CHEBI:5686" relevant="false" type="CLASS">heterocyclic compound</ne> with at least one atom of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.265" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne> is chosen from <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.278" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> or <ne id="WO2007045675.HC.class-names.83" epochem-id="EPOCHEM:NEW:CLASS:805" name="pyridines" comment="" chebi-id="CHEBI:26421" relevant="false" type="CLASS">pyridines</ne> substituted with one or more <ne type="LIGAND" id="WO2007045675.HC.ligand-names.6" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> groups, such as <ne id="WO2007045675.HC.class-names.132" epochem-id="EPOCHEM:NEW:CLASS:1068" name="collidines" comment="" chebi-id="WO2007045675:946337" relevant="false" type="CLASS">collidines</ne> or <ne id="WO2007045675.HC.class-names.3" epochem-id="EPOCHEM:NEW:CLASS:161" name="lutidines" comment="" chebi-id="WO2007045675:273306" relevant="false" type="CLASS">lutidines</ne>; or <ne id="WO2007045675.HC.class-names.37" epochem-id="EPOCHEM:NEW:CLASS:168" name="imidazole" comment="" chebi-id="CHEBI:16069" relevant="false" type="CLASS">imidazole</ne> or <ne id="WO2007045675.HC.class-names.38" epochem-id="EPOCHEM:NEW:CLASS:168" name="imidazole" comment="" chebi-id="CHEBI:16069" relevant="false" type="CLASS">imidazole</ne> substituted with a <ne type="LIGAND" id="WO2007045675.HC.ligand-names.7" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> group such as <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.57" epochem-id="EPOCHEM:NEW:COMPOUND:759" name="2- methylimidazole" comment="" chebi-id="WO2007045675:164819" relevant="false">2-methylimidazole</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.115" epochem-id="EPOCHEM:NEW:COMPOUND:774" name="4-methylimidazole" comment="" chebi-id="WO2007045675:888814" relevant="false">4-methylimidazole</ne> . More preferably still, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.58" epochem-id="EPOCHEM:NEW:COMPOUND:759" name="2- methylimidazole" comment="" chebi-id="WO2007045675:164819" relevant="false">2- methylimidazole</ne> is used.
The reaction of step c) takes place in the presence of 1 or 2 equivalents of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.110" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> in relation to the amount of starting product (VI). Advantageously, the presence of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.111" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> in said reaction prevents racemisation of the asymmetric carbon.
Advantageously, said N-acylation is carried out at a temperature between -10 and 10&lt;0&gt;C.
In accordance with the second aspect of the invention, a method is provided for obtaining the synthesis intermediate (II) with few synthesis steps, where the compound of formula (VI) can be obtained by means of a one-pot reaction from the starting products
(VII) and (IV), without need to isolate the <ne id="WO2007045675.HC.class-names.89" epochem-id="EPOCHEM:NEW:CLASS:1020" name="imine" comment="" chebi-id="CHEBI:24783" relevant="false" type="CLASS">imine</ne> compound (VIII) .
With the process according to the second aspect of the invention the compound of formula (II) is achieved with good yields and in two reaction steps, since the one- pot reaction is carried out according to the conditions set out in steps a) and b) to obtain the compound of formula (VI) from simple and commercially available raw materials .
Finally, the product obtained according to the first or second aspects of the invention can be purified by conventional methods such as recrystallisation in a single solvent or in a mixture of a solvent and antisolvent, for example <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.102" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>/<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.112" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.93" epochem-id="EPOCHEM:COMPOUND:4306" name="ethyl acetate" comment="" chebi-id="CHEBI:27750" relevant="false">ethyl acetate</ne>/ <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.94" epochem-id="EPOCHEM:COMPOUND:5452" name="hexane" comment="" chebi-id="CHEBI:29021" relevant="false">hexane</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.95" epochem-id="EPOCHEM:COMPOUND:5443" name="dichloromethane" comment="" chebi-id="CHEBI:15767" relevant="false">dichloromethane</ne>/<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.96" epochem-id="EPOCHEM:NEW:COMPOUND:771" name="heptane" comment="" chebi-id="CHEBI:43098" relevant="false">heptane</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.98" epochem-id="EPOCHEM:NEW:COMPOUND:772" name="isopropyl acetate" comment="" chebi-id="WO2007045675:674892" relevant="false">isopropyl acetate</ne>/<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.99" epochem-id="EPOCHEM:NEW:COMPOUND:773" name="methylcyclohexane" comment="" chebi-id="WO2007045675:926201" relevant="false">methylcyclohexane</ne> .
Surprisingly and unexpectedly, according to the first and second aspects the invention provides a method for obtaining the intermediate of formula (II) without racemisation from a compound of formula (VI) that does not require the protection of the <ne id="WO2007045675.HC.class-names.22" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne>.
Advantageously, the compound of formula (VI) is obtained with an optical purity of 99.5-100%.
The process described according to the first and the second aspects of the invention permits very good qualities of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.11" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> to be obtained and, therefore, the process of subsequent purification of said active ingredient is greatly simplified.
The process of formula (I) for obtaining <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.12" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne>, by means of coupling of the intermediate of formula (VI), referenced in the present invention as intermediate of formula (II), with the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.262" epochem-id="EPOCHEM:COMPOUND:7221" name="boronic acid" comment="" chebi-id="CHEBI:38267" relevant="false">boronic acid</ne> of formula (VII), is the object of the patent application ES200400949:
EMI16.1
In said application <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.13" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne> is obtained with good chemical yield and high optical purity by means of a process applicable on an industrial scale and starting from simple and commercially available products through synthesis intermediates that do not require protection of the tetrazolic ring or of the <ne id="WO2007045675.HC.class-names.23" epochem-id="EPOCHEM:NEW:CLASS:112" name="carboxylic acid" comment="" chebi-id="CHEBI:33575" relevant="false" type="CLASS">carboxylic acid</ne> of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.168" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L- Valine</ne> moiety, nor the use of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.153" epochem-id="EPOCHEM:NEW:COMPOUND:783" name="sodium azide" comment="" chebi-id="WO2007045675:830012" relevant="false">sodium azide</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.155" epochem-id="EPOCHEM:NEW:COMPOUND:784" name="tributyl tin azide" comment="" chebi-id="WO2007045675:641943" relevant="false">tributyl tin azide</ne>, thereby improving the safety of the process and reducing its environmental impact.
There follow some examples which, by way of non- restrictive example, show some preferred embodiments of the various aspects thereof.
EXAMPLES
Example 1 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.84" epochem-id="EPOCHEM:NEW:COMPOUND:767" name="N- (4- bromobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:280351" relevant="true">N- (4-bromobenzyl) -L-Valine</ne>
To a mixture formed by 11.7g (100 mmol) of L-
<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.213" epochem-id="EPOCHEM:COMPOUND:1055" name="valine" comment="" chebi-id="CHEBI:27266" relevant="false">Valine</ne>, 100 mL of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.247" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> and 21 mL (110 mmol) of a 30% methanolic solution of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.89" epochem-id="EPOCHEM:NEW:COMPOUND:770" name="sodium methoxide" comment="" chebi-id="WO2007045675:912852" relevant="false">sodium methoxide</ne> is added 16.7 g (90 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.257" epochem-id="EPOCHEM:NEW:COMPOUND:793" name="4-bromobenzaldhehyde" comment="" chebi-id="WO2007045675:395672" relevant="false">4-bromobenzaldhehyde</ne>, and this is stirred for Ih. The mixture is cooled to -10 &lt;0&gt;C and 1.9g (50 mmol) of <ne type="FORMULA" id="WO2007045675.HC.formula-names.1" epochem-id="EPOCHEM:NEW:FORMULA:47" name="NaBH4" comment="" chebi-id="WO2007045675:487488" relevant="false">NaBH4</ne> is added in portions, keeping the temperature below 0 &lt;0&gt;C. After 90 minutes of reaction time, 100 mL of <ne type="FORMULA" id="WO2007045675.HC.formula-names.5" epochem-id="EPOCHEM:NEW:FORMULA:7" name="H2O" comment="" chebi-id="CHEBI:15377" relevant="false">H2O</ne> are added slowly followed by 20 mL of toluene and the pH is adjusted to 5 with <ne type="FORMULA" id="WO2007045675.HC.formula-names.18" epochem-id="EPOCHEM:NEW:FORMULA:106" name="HCl" comment="" chebi-id="CHEBI:17883" relevant="false">HCl</ne> 3N. The solid obtained is filtered and washed with <ne type="FORMULA" id="WO2007045675.HC.formula-names.6" epochem-id="EPOCHEM:NEW:FORMULA:7" name="H2O" comment="" chebi-id="CHEBI:15377" relevant="false">H2O</ne> to give 23.7g (92%) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.85" epochem-id="EPOCHEM:NEW:COMPOUND:767" name="N- (4- bromobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:280351" relevant="true">N- (4- bromobenzyl) -L-Valine</ne> .
Min. DSC = 256.6 &lt;0&gt;C [[alpha]]= 17.6[deg.]
The enantiomeric purity is determined by chiral HPLC giving e.e=100%
IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.20" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2962, 1606, 1447, 1388, 1208, 1013, 872, 793. NMR IH (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.273" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>, 60 &lt;0&gt;C), - (ppm) : 0.91 (d, 6H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.58" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">- CH(CH3)2</ne>); 1.7-1.9 (m, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.59" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne>); 2.84 (d, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.44" epochem-id="EPOCHEM:NEW:LIGAND:507" name="-CHCO2H" comment="" chebi-id="WO2007045675:980881" relevant="false">- CHCO2H</ne>) ; 3.7 (dd, 2H, Ar-CH2-) ; 7.3 (d, 2H, ArH); 7.5 (d, 2H, ArH) .
Example 2 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.78" epochem-id="EPOCHEM:NEW:COMPOUND:764" name="N- (4-chlorobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:454774" relevant="true">N- (4-chlorobenzyl) -L-Valine</ne>
In a manner similar to Example 1 and starting out from 11.7g (100 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.172" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne>, 21 mL (110 mmol) of 30% methanolic solution of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.90" epochem-id="EPOCHEM:NEW:COMPOUND:770" name="sodium methoxide" comment="" chebi-id="WO2007045675:912852" relevant="false">sodium methoxide</ne>, 12.7g (90 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.194" epochem-id="EPOCHEM:NEW:COMPOUND:786" name="4-chlorobenzaldhehyde" comment="" chebi-id="WO2007045675:931385" relevant="false">4-chlorobenzaldhehyde</ne> and 1.9g (50 mmol) of <ne type="FORMULA" id="WO2007045675.HC.formula-names.2" epochem-id="EPOCHEM:NEW:FORMULA:47" name="NaBH4" comment="" chebi-id="WO2007045675:487488" relevant="false">NaBH4</ne>,
</P>
<P>17.8g (82%) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.79" epochem-id="EPOCHEM:NEW:COMPOUND:764" name="N- (4-chlorobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:454774" relevant="true">N- (4-chlorobenzyl) -L-Valine</ne> is obtained.
Min. DSC = 241.8 &lt;0&gt;C [[alpha]]= 20.1[deg.] IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.21" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2960, 1599, 1485, 1444, 1351, 1287, 1209, 1091, 1017, 834.
NMR IH (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.274" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>, 60 &lt;0&gt;C) , (ppm) : 0. 91 (d, 6H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.60" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">- CH(CH3)2</ne>); 1.7-1.9 (m, IH, -C (CH3)2) ; 2.i 34 (d, IH, -
CHCO2H) ; 3.7 (dd, 2H, Ar-CH2-) ; 7.4 (s, 4H, ArH). Example 3 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.258" epochem-id="EPOCHEM:NEW:COMPOUND:794" name="N- ( 4 - idoben z yl ) -L-Val ine" comment="N- (4 - iodobenzyl) - L - Valine" chebi-id="WO2007045675:92336" relevant="true">N- ( 4 - idoben z yl ) -L-Val ine</ne>
In a manner similar to Example 1 and starting out from 454 mg (3.87 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.174" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne>, 1 mL (5.39 mmol) of 30% methanolic solution of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.91" epochem-id="EPOCHEM:NEW:COMPOUND:770" name="sodium methoxide" comment="" chebi-id="WO2007045675:912852" relevant="false">sodium methoxide</ne>, Ig (4.31 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.88" epochem-id="EPOCHEM:NEW:COMPOUND:769" name="4-iodobenzaldhehyde" comment="" chebi-id="WO2007045675:496383" relevant="false">4-iodobenzaldhehyde</ne> and 83mg (2.2 mmol) of <ne type="FORMULA" id="WO2007045675.HC.formula-names.3" epochem-id="EPOCHEM:NEW:FORMULA:47" name="NaBH4" comment="" chebi-id="WO2007045675:487488" relevant="false">NaBH4</ne>,
Ig (70%) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.74" epochem-id="EPOCHEM:NEW:COMPOUND:762" name="N- (4-iodobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:617798" relevant="false">N- (4-iodobenzyl) -L-Valine</ne> is obtained.
Min. DSC = 264.2 &lt;0&gt;C [[alpha]]= 13.3[deg.]
IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.22" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2952, 1610, 1485, 1446, 1348, 1284, 1206, 1006, 824, 789.
NMR IH (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.275" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>, 60 &lt;0&gt;C), - (ppm) : 0.93 (d, 6H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.61" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">- CH(CH3)2</ne>); 1.7-1.9 (m, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.62" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne>); 2.81 (d, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.45" epochem-id="EPOCHEM:NEW:LIGAND:507" name="-CHCO2H" comment="" chebi-id="WO2007045675:980881" relevant="false">- CHCO2H</ne>) ; 3.7 (dd, 2H, Ar-CH2-) ; 7.2 (d, 2H, ArH); 7.7 (d, 2H, ArH) .
Example 4 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.87" epochem-id="EPOCHEM:NEW:COMPOUND:768" name="N- (4- (toluen-4-sulphonyl) -benzyl) -L- Valine" comment="" chebi-id="WO2007045675:706460" relevant="true">N- (4- (toluen-4-sulphonyl) -benzyl) -L- Valine</ne>
In a manner similar to Example 1 and starting out from 8.5g (72.5 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.177" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne>, 16 mL (86.3 mmol) of 30% methanolic solution of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.92" epochem-id="EPOCHEM:NEW:COMPOUND:770" name="sodium methoxide" comment="" chebi-id="WO2007045675:912852" relevant="false">sodium methoxide</ne>, 20g (72.5 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.195" epochem-id="EPOCHEM:NEW:COMPOUND:787" name="4-tosylbenzaldhehyde" comment="" chebi-id="WO2007045675:277583" relevant="false">4-tosylbenzaldhehyde</ne> and 1.4g (37 mmol) of <ne type="FORMULA" id="WO2007045675.HC.formula-names.4" epochem-id="EPOCHEM:NEW:FORMULA:47" name="NaBH4" comment="" chebi-id="WO2007045675:487488" relevant="false">NaBH4</ne>, 20g (73%) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.272" epochem-id="EPOCHEM:NEW:COMPOUND:1379" name="N- (4-toluen-4-sulphonyl) -benzyl) -L-Valine" comment="" chebi-id="WO2007045675:451183" relevant="true">N- (4-toluen-4-sulphonyl) -benzyl) -L-Valine</ne> is obtained.
Min. DSC = 219.5 &lt;0&gt;C [[alpha]]= 12.3[deg.] IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.23" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2957, 1606, 1443, 1373, 1090, 1017, 867, 746, 698.
NMR IH (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.276" epochem-id="EPOCHEM:NEW:COMPOUND:937" name="DMSO" comment="" chebi-id="CHEBI:28262" relevant="false">DMSO</ne>, 60 &lt;0&gt;C), - (ppm): 0.91 (d, 6H, -
<ne type="FORMULA" id="WO2007045675.HC.formula-names.31" epochem-id="EPOCHEM:NEW:FORMULA:243" name="CH(CH3)2" comment="" chebi-id="WO2007045675:290290" relevant="false">CH(CH3)2</ne>); 1.7-1.9 (m, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.63" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne>); 2.5 (s, 3H, H3C-Ar-
SO2-); 2.82 (d, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.46" epochem-id="EPOCHEM:NEW:LIGAND:507" name="-CHCO2H" comment="" chebi-id="WO2007045675:980881" relevant="false">-CHCO2H</ne>) ; 3.7 (dd, 2H, Ar-CH2-) ; 7.3 (d, 2H, ArH); 7.5 (d, 2H, ArH); 7.0 (d, 2H, O2SArH-CH3); 7 . 7 ( d, 2H , O2 SArH-CH3 ) .
Example 5 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.83" epochem-id="EPOCHEM:NEW:COMPOUND:766" name="N- (4-bromobenzyl) -N-valeryl-L-Valine" comment="" chebi-id="WO2007045675:546087" relevant="true">N- (4-bromobenzyl) -N-valeryl-L-Valine</ne> .
A mixture formed by 11.4g (40 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.86" epochem-id="EPOCHEM:NEW:COMPOUND:767" name="N- (4- bromobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:280351" relevant="true">N- (4- bromobenzyl) -L-Valine</ne> and 60 mL of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.251" epochem-id="EPOCHEM:NEW:COMPOUND:791" name="THF" comment="" chebi-id="WO2007045675:52513" relevant="false">THF</ne> is cooled to -5 &lt;0&gt;C, and 2.8 mL (50 mmol) of HAcO, 7.6 mL (64 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.68" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne> and a solution of 4.9g (60 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.59" epochem-id="EPOCHEM:NEW:COMPOUND:759" name="2- methylimidazole" comment="" chebi-id="WO2007045675:164819" relevant="false">2- methylimidazole</ne> in 30 mL of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.252" epochem-id="EPOCHEM:NEW:COMPOUND:791" name="THF" comment="" chebi-id="WO2007045675:52513" relevant="false">THF</ne> and 1.4 mL (80 mmol) of <ne type="FORMULA" id="WO2007045675.HC.formula-names.7" epochem-id="EPOCHEM:NEW:FORMULA:7" name="H2O" comment="" chebi-id="CHEBI:15377" relevant="false">H2O</ne> are added to it. The reaction mixture is stirred for 30 minutes at room temperature, 10 mL of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.248" epochem-id="EPOCHEM:COMPOUND:4792" name="methanol" comment="" chebi-id="CHEBI:17790" relevant="false">methanol</ne> is added to it, it is then stirred for a further 15 minutes and 40 mL of <ne type="FORMULA" id="WO2007045675.HC.formula-names.8" epochem-id="EPOCHEM:NEW:FORMULA:7" name="H2O" comment="" chebi-id="CHEBI:15377" relevant="false">H2O</ne> is added to it. The phases are separated and the organic phase is evaporated to dryness and the solid obtained is recrystallised from a mixture of EtOHiH2O 1:1.
Min. DSC = 134.3 &lt;0&gt;C [[alpha]]=-68[deg.]
The enantiomeric purity is determined by chiral HPLC, giving e.e=100%
IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.24" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2957, 1720, 1591, 1472, 1247, 1012, 786.
NMR IH (CDCl3), - (ppm) : 0.8-1.1 (m, 9H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.64" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne> + <ne type="LIGAND" id="WO2007045675.HC.ligand-names.36" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.2-1.5 (m, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.37" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.5-1.8 (m, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.55" epochem-id="EPOCHEM:NEW:LIGAND:509" name="- CH2CH2CH3" comment="" chebi-id="WO2007045675:610391" relevant="false">- CH2CH2CH3</ne>) ; 2.4 (t, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.51" epochem-id="EPOCHEM:NEW:LIGAND:508" name="-CH2CO-" comment="" chebi-id="WO2007045675:49812" relevant="false">-CH2CO-</ne>) ; 2.5-2.7 (m, IH,
<ne type="LIGAND" id="WO2007045675.HC.ligand-names.84" epochem-id="EPOCHEM:NEW:LIGAND:599" name="CH(CH3)2" comment="" chebi-id="WO2007045675:849415" relevant="false">CH(CH3)2</ne>); 3.8 (d, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.47" epochem-id="EPOCHEM:NEW:LIGAND:507" name="-CHCO2H" comment="" chebi-id="WO2007045675:980881" relevant="false">-CHCO2H</ne>) ; 4.6 (dd, 2H, Ar-CH2-) ; 7.1 (d, 2H, ArH); 7.5 (d, 2H, ArH).
Example 6 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.81" epochem-id="EPOCHEM:NEW:COMPOUND:765" name="N- (4-chlorobenzyl) -N-valeryl-L-Valine" comment="" chebi-id="WO2007045675:126056" relevant="true">N- (4-chlorobenzyl) -N-valeryl-L-Valine</ne> .
In a manner similar to Example 5 and starting from
</P>
<P>15g (62 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.80" epochem-id="EPOCHEM:NEW:COMPOUND:764" name="N- (4-chlorobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:454774" relevant="true">N- (4-chlorobenzyl) -L-Valine</ne>, 12 mL (99 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.69" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne> and 7.7g (93 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.60" epochem-id="EPOCHEM:NEW:COMPOUND:759" name="2- methylimidazole" comment="" chebi-id="WO2007045675:164819" relevant="false">2- methylimidazole</ne>, 15.7g (77%) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.82" epochem-id="EPOCHEM:NEW:COMPOUND:765" name="N- (4-chlorobenzyl) -N-valeryl-L-Valine" comment="" chebi-id="WO2007045675:126056" relevant="true">N- (4-chlorobenzyl) -N- valeryl-L-Valine</ne> is obtained. The solid is recrystallised from a mixture of <ne type="FORMULA" id="WO2007045675.HC.formula-names.19" epochem-id="EPOCHEM:NEW:FORMULA:6" name="EtOH" comment="" chebi-id="CHEBI:16236" relevant="false">EtOH</ne> i <ne type="FORMULA" id="WO2007045675.HC.formula-names.9" epochem-id="EPOCHEM:NEW:FORMULA:7" name="H2O" comment="" chebi-id="CHEBI:15377" relevant="false">H2O</ne> 1 : 1 .
Min . DSC = 128 . 1 &lt;0&gt; C [ [alpha]] =-77 . 9 [deg.]
</P>
<P>5 IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.25" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2957, 1714, 1588, 1471, 1403, 1246, 1095, 792.
NMR IH (CDC13), - (ppm) : 0.8-1.1 (m, 9H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.65" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne> + <ne type="LIGAND" id="WO2007045675.HC.ligand-names.38" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.2-1.5 (m, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.39" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.5-1.8 (m, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.56" epochem-id="EPOCHEM:NEW:LIGAND:509" name="- CH2CH2CH3" comment="" chebi-id="WO2007045675:610391" relevant="false">- CH2CH2CH3</ne>); 2.4 (t, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.52" epochem-id="EPOCHEM:NEW:LIGAND:508" name="-CH2CO-" comment="" chebi-id="WO2007045675:49812" relevant="false">-CH2CO-</ne>) ; 2.5-2.7 (m, IH, 10 <ne type="LIGAND" id="WO2007045675.HC.ligand-names.89" epochem-id="EPOCHEM:NEW:LIGAND:599" name="CH(CH3)2" comment="" chebi-id="WO2007045675:989544" relevant="false">CH(CH3)2</ne>); 3.8 (d, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.48" epochem-id="EPOCHEM:NEW:LIGAND:507" name="-CHCO2H" comment="" chebi-id="WO2007045675:980881" relevant="false">-CHCO2H</ne>) ; 4.6 (dd, 2H, Ar-CH2-) ; 7.1 (d, 2H, ArH); 7.3 (d, 2H, ArH).
Example 7 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.76" epochem-id="EPOCHEM:NEW:COMPOUND:763" name="N- (4-iodobenzyl) -N- valeryl-L-Valine" comment="" chebi-id="WO2007045675:908242" relevant="true">N- (4-iodobenzyl) -N-valeryl-L-Valine</ne> .
</P>
<P>15 In a manner similar to Example 5 and starting from
</P>
<P>800 mg (2.40 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.75" epochem-id="EPOCHEM:NEW:COMPOUND:762" name="N- (4-iodobenzyl) -L-Valine" comment="" chebi-id="WO2007045675:617798" relevant="false">N- (4-iodobenzyl) -L-Valine</ne>, 0.47 mL
(3.84 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.70" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne> and 296 mg (3.60 mmol) of
<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.61" epochem-id="EPOCHEM:NEW:COMPOUND:759" name="2- methylimidazole" comment="" chebi-id="WO2007045675:164819" relevant="false">2-methylimidazole</ne>, 635 mg (64%) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.77" epochem-id="EPOCHEM:NEW:COMPOUND:763" name="N- (4-iodobenzyl) -N- valeryl-L-Valine" comment="" chebi-id="WO2007045675:908242" relevant="true">N- (4-iodobenzyl) -N- valeryl-L-Valine</ne> is obtained. The solid is recrystallised
</P>
<P>20 from a mixture of EtOHiH2O 1:1.
Min. DSC = 129.5 &lt;0&gt;C [[alpha]]=-52.9[deg.]
IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.26" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2957, 1719, 1588, 1469, 1403, 25 1247, 1173, 1105, 1003, 966, 847, 783.
NMR IH (CDC13), - (ppm): 0.8-1.1 (m, 9H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.66" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne>
+ <ne type="LIGAND" id="WO2007045675.HC.ligand-names.40" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.2-1.5 (m, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.41" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.5-1.8 (m, 2H, -
CH2CH2CH3); 2.4 (t, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.53" epochem-id="EPOCHEM:NEW:LIGAND:508" name="-CH2CO-" comment="" chebi-id="WO2007045675:49812" relevant="false">-CH2CO-</ne>) ; 2.5-2.7 (m, IH, -
<ne type="LIGAND" id="WO2007045675.HC.ligand-names.90" epochem-id="EPOCHEM:NEW:LIGAND:599" name="CH(CH3)2" comment="" chebi-id="WO2007045675:912334" relevant="false">CH(CH3)2</ne>); 3.8 (d, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.49" epochem-id="EPOCHEM:NEW:LIGAND:507" name="-CHCO2H" comment="" chebi-id="WO2007045675:980881" relevant="false">-CHCO2H</ne>) ; 4.6 (dd, 2H, Ar-CH2-) ;
</P>
<P>30 7.0 (d, 2H, ArH); 7.7 (d, 2H, ArH).
Example 8 : <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.53" epochem-id="EPOCHEM:NEW:COMPOUND:755" name="N- (4- (toluen-4-sulphonyl) -benzyl) -N- valeryl-L-Valine" comment="" chebi-id="WO2007045675:172127" relevant="true">N- (4- (toluen-4-sulphonyl) -benzyl) -N- valeryl-L-Valine</ne> .
</P>
<P>35 In a manner similar to Example 5 and starting from 12g (32 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.56" epochem-id="EPOCHEM:NEW:COMPOUND:758" name="N- (4-tosylbenzyl) -L-Valine" comment="" chebi-id="WO2007045675:602482" relevant="false">N- (4-tosylbenzyl) -L-Valine</ne>, 6.2 mL (51 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.71" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne> and 3.95g (48 mmol) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.62" epochem-id="EPOCHEM:NEW:COMPOUND:759" name="2- methylimidazole" comment="" chebi-id="WO2007045675:164819" relevant="false">2- methylimidazole</ne>, Hg (75%) of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.54" epochem-id="EPOCHEM:NEW:COMPOUND:756" name="N- (4-toluen-4-sulphonyl) - benzyl) -N-valeryl-L-Valine" comment="" chebi-id="WO2007045675:250712" relevant="false">N- (4-toluen-4-sulphonyl) - benzyl) -N-valeryl-L-Valine</ne> is obtained. The solid is 5 recrystallised from a mixture of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.55" epochem-id="EPOCHEM:NEW:COMPOUND:757" name="n-Heptane" comment="" chebi-id="CHEBI:43098" relevant="false">n-Heptane</ne>: <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.73" epochem-id="EPOCHEM:NEW:COMPOUND:761" name="EtAcO" comment="" chebi-id="WO2007045675:640744" relevant="false">EtAcO</ne> 10:1.
Min. DSC = 98.1 &lt;0&gt;C
</P>
<P>[[alpha]]=-57.1[deg.]
IR (<ne type="FORMULA" id="WO2007045675.HC.formula-names.27" epochem-id="EPOCHEM:NEW:FORMULA:146" name="KBr" comment="" chebi-id="CHEBI:32030" relevant="false">KBr</ne>, cm-1) : 2957, 1714, 1575, 1469, 1362, 10 1249, 1173, 1092, 862, 748, 688, 660.
NMR IH (CDC13), - (ppm) : 0.8-1.1 (m, 9H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.67" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne> + <ne type="LIGAND" id="WO2007045675.HC.ligand-names.42" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.2-1.5 (m, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.43" epochem-id="EPOCHEM:NEW:LIGAND:506" name="-CH2CH3" comment="" chebi-id="WO2007045675:401275" relevant="false">-CH2CH3</ne>); 1.5-1.8 (m, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.57" epochem-id="EPOCHEM:NEW:LIGAND:509" name="- CH2CH2CH3" comment="" chebi-id="WO2007045675:610391" relevant="false">- CH2CH2CH3</ne>); 2.3 (t, 2H, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.54" epochem-id="EPOCHEM:NEW:LIGAND:508" name="-CH2CO-" comment="" chebi-id="WO2007045675:49812" relevant="false">-CH2CO-</ne>) ; 2.4 (s, 3H, SO2ArCH3); 2.6 (m, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.68" epochem-id="EPOCHEM:NEW:LIGAND:510" name="- CH(CH3)2" comment="" chebi-id="WO2007045675:717404" relevant="false">-CH(CH3)2</ne>); 3.7 (d, IH, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.50" epochem-id="EPOCHEM:NEW:LIGAND:507" name="-CHCO2H" comment="" chebi-id="WO2007045675:980881" relevant="false">-CHCO2H</ne>) ; 4.6 (dd, 2H, 15 Ar-CH2-) ; 7.1 (d, 2H, ArH); 7.3 (d, 2H, ArH); 7.0 (d, 2H, O2SArH-CH3); 7.7 (d, 2H, O2SArH-CH3).
C L A I M S
</P>
<P>1. Process for obtaining the synthesis intermediate of formula (II) useful for the synthesis of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.14" epochem-id="EPOCHEM:NEW:COMPOUND:754" name="Valsartan" comment="" chebi-id="CHEBI:9927" relevant="true">Valsartan</ne>, characterised in that it comprises:
EMI22.1
a) Imination of the <ne id="WO2007045675.HC.class-names.69" epochem-id="EPOCHEM:NEW:CLASS:392" name="aldehyde" comment="" chebi-id="CHEBI:17478" relevant="false" type="CLASS">aldehyde</ne> group of a compound of formula (VII) by <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.190" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> (IV) salts with organic or <ne type="ONT" id="WO2007045675.HC.class-names.106" epochem-id="EPOCHEM:NEW:CLASS:1062" name="inorganic bases" comment="" chebi-id="WO2007045675:320986" relevant="false">inorganic bases</ne> and a <ne type="ONT" id="WO2007045675.HC.class-names.81" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.113" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne>:
EMI22.2
where:
X means <ne id="WO2007045675.HC.class-names.94" epochem-id="EPOCHEM:NEW:CLASS:132" name="halogen" comment="" chebi-id="CHEBI:24473" relevant="false" type="CLASS">halogen</ne> or an-0SU2R group, where R is <ne type="FORMULA" id="WO2007045675.HC.formula-names.13" epochem-id="EPOCHEM:NEW:FORMULA:42" name="CF3" comment="" chebi-id="WO2007045675:424416" relevant="false">CF3</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.26" epochem-id="EPOCHEM:NEW:LIGAND:373" name="tolyl" comment="" chebi-id="WO2007045675:17853" relevant="false">tolyl</ne>, <ne type="LIGAND" id="WO2007045675.HC.ligand-names.8" epochem-id="EPOCHEM:NEW:LIGAND:346" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne> or <ne type="FORMULA" id="WO2007045675.HC.formula-names.17" epochem-id="EPOCHEM:NEW:FORMULA:22" name="F" comment="" chebi-id="CHEBI:29997,CHEBI:24061,CHEBI:17295" relevant="false">F</ne>;
to give an <ne id="WO2007045675.HC.class-names.90" epochem-id="EPOCHEM:NEW:CLASS:1020" name="imine" comment="" chebi-id="CHEBI:24783" relevant="false" type="CLASS">imine</ne>-type compound or <ne type="ONT" id="WO2007045675.HC.class-names.15" epochem-id="EPOCHEM:NEW:CLASS:163" name="Schiff base" comment="" chebi-id="WO2007045675:664871" relevant="false">Schiff base</ne> of formula (VIII) :
EMI22.3
where :
X has the meaning defined above and B&lt;+&gt; is the protonated form of an <ne type="ONT" id="WO2007045675.HC.class-names.123" epochem-id="EPOCHEM:NEW:CLASS:1064" name="organic base" comment="" chebi-id="WO2007045675:926339" relevant="false">organic base</ne> or an alkaline cation.
</P>
<P>2 b) Reduction of the <ne type="LIGAND" id="WO2007045675.HC.ligand-names.35" epochem-id="EPOCHEM:NEW:LIGAND:505" name="imine group" comment="should be &quot;imino group&quot;" chebi-id="CHEBI:29342" relevant="false">imine group</ne> of the compound of formula (VIII) followed by acidification, to give the compound of formula (VI) :
EMI23.1
c) N-Acylation of the compound of formula (VI) with <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.72" epochem-id="EPOCHEM:NEW:COMPOUND:760" name="valeryl chloride" comment="" chebi-id="WO2007045675:603229" relevant="false">valeryl chloride</ne> to give the compound of formula
EMI23.2
</P>
<P>2. Process according to claim 1, characterised in that said organic or <ne type="ONT" id="WO2007045675.HC.class-names.109" epochem-id="EPOCHEM:NEW:CLASS:550" name="inorganic base" comment="" chebi-id="WO2007045675:658098" relevant="false">inorganic base</ne> is in equimolar proportion in relation to the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.191" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne>.
</P>
<P>3. Process according to claim 1, characterised in that in said step a) said <ne type="ONT" id="WO2007045675.HC.class-names.124" epochem-id="EPOCHEM:NEW:CLASS:1064" name="organic base" comment="" chebi-id="WO2007045675:926339" relevant="false">organic base</ne> is chosen from a substituted amine-type compound to form a salt of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.192" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L- Valine</ne> with an <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.277" epochem-id="EPOCHEM:COMPOUND:4221" name="ammonium" comment="" chebi-id="CHEBI:28938" relevant="false">ammonium</ne> cation; an alcoxide or metallic <ne id="WO2007045675.HC.class-names.52" epochem-id="EPOCHEM:NEW:CLASS:387" name="hydroxide" comment="" chebi-id="CHEBI:16234" relevant="false" type="CLASS">hydroxide</ne> to form a salt of the <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.193" epochem-id="EPOCHEM:NEW:COMPOUND:785" name="L- Valine" comment="" chebi-id="WO2007045675:172838" relevant="true">L-Valine</ne> with an <ne id="WO2007045675.HC.class-names.55" epochem-id="EPOCHEM:NEW:CLASS:388" name="alkaline metal" comment="" chebi-id="WO2007045675:764631" relevant="false" type="CLASS">alkaline metal</ne> .
</P>
<P>4. Process according to claim 1, characterised in that said step a) of imination is carried out at a temperature between 0&lt;0&gt;C and the boiling temperature of the solvent .
</P>
<P>5. Process according to claim 4, characterised in that said temperature is between 10&lt;0&gt;C and 35[deg.]C.
</P>
<P>3
</P>
<P>6. Process according to claim 1, characterised in that said solvent is chosen from a protic <ne type="ONT" id="WO2007045675.HC.class-names.82" epochem-id="EPOCHEM:NEW:CLASS:489" name="polar solvent" comment="" chebi-id="WO2007045675:772686" relevant="false">polar solvent</ne>.
</P>
<P>7. Process according to claim 6, characterised in that said solvent is an <ne id="WO2007045675.HC.class-names.27" epochem-id="EPOCHEM:NEW:CLASS:100" name="alcohol" comment="" chebi-id="CHEBI:30879" relevant="false" type="CLASS">alcohol</ne>.
</P>
<P>8. Process according to claim 1, characterised in that in step b) the reduction reaction takes place in an alcoholic medium using a borohydride as <ne type="ONT" id="WO2007045675.HC.class-names.12" epochem-id="EPOCHEM:NEW:CLASS:162" name="reducing agent" comment="" chebi-id="WO2007045675:343501" relevant="false">reducing agent</ne>.
</P>
<P>9. Process according to claim 8, characterised in that said borohydride is chosen from <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.146" epochem-id="EPOCHEM:NEW:COMPOUND:781" name="sodium borohydride" comment="" chebi-id="WO2007045675:460406" relevant="false">sodium borohydride</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.141" epochem-id="EPOCHEM:NEW:COMPOUND:779" name="lithium borohydride" comment="" chebi-id="WO2007045675:335475" relevant="false">lithium borohydride</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.143" epochem-id="EPOCHEM:NEW:COMPOUND:780" name="calcium borohydride" comment="" chebi-id="WO2007045675:504211" relevant="false">calcium borohydride</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.139" epochem-id="EPOCHEM:NEW:COMPOUND:778" name="sodium cyanoborohydride" comment="" chebi-id="WO2007045675:471961" relevant="false">sodium cyanoborohydride</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.137" epochem-id="EPOCHEM:NEW:COMPOUND:534" name="sodium triacetoxyborohydride" comment="" chebi-id="WO2007045675:248154" relevant="false">sodium triacetoxyborohydride</ne> .
</P>
<P>10. Process according to claim 1, characterised in that in step b) the reduction reaction is carried out by means of catalytic hydrogenation in the presence of hydrogen and of a <ne type="ONT" id="WO2007045675.HC.class-names.60" epochem-id="EPOCHEM:NEW:CLASS:390" name="metallic catalyst" comment="" chebi-id="WO2007045675:926372" relevant="false">metallic catalyst</ne> at atmospheric pressure or by means of hydrogen transfer in the presence of a <ne type="ONT" id="WO2007045675.HC.class-names.61" epochem-id="EPOCHEM:NEW:CLASS:390" name="metallic catalyst" comment="" chebi-id="WO2007045675:926372" relevant="false">metallic catalyst</ne> and a <ne type="ONT" id="WO2007045675.HC.class-names.64" epochem-id="EPOCHEM:NEW:CLASS:391" name="hydrogen donor" comment="" chebi-id="CHEBI:17499" relevant="false">hydrogen donor</ne>.
</P>
<P>11. Process according to claim 10, characterised in that said <ne type="ONT" id="WO2007045675.HC.class-names.62" epochem-id="EPOCHEM:NEW:CLASS:390" name="metallic catalyst" comment="" chebi-id="WO2007045675:926372" relevant="false">metallic catalyst</ne> is chosen from <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.126" epochem-id="EPOCHEM:NEW:COMPOUND:777" name="Raney-Nickel" comment="" chebi-id="WO2007045675:97041" relevant="false">Raney-Nickel</ne> or a catalyst of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.130" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.259" epochem-id="EPOCHEM:COMPOUND:7464" name="platinum" comment="" chebi-id="CHEBI:33364" relevant="false">platinum</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.133" epochem-id="EPOCHEM:COMPOUND:7460" name="rhodium" comment="" chebi-id="CHEBI:33359" relevant="false">rhodium</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.135" epochem-id="EPOCHEM:COMPOUND:7457" name="ruthenium" comment="" chebi-id="CHEBI:30682" relevant="false">ruthenium</ne>, preferably <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.131" epochem-id="EPOCHEM:COMPOUND:7463" name="palladium" comment="" chebi-id="CHEBI:33363" relevant="false">palladium</ne>.
</P>
<P>12. Process according to claim 10, characterised in that said <ne type="ONT" id="WO2007045675.HC.class-names.65" epochem-id="EPOCHEM:NEW:CLASS:391" name="hydrogen donor" comment="" chebi-id="CHEBI:17499" relevant="false">hydrogen donor</ne> is chosen from <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.148" epochem-id="EPOCHEM:COMPOUND:601" name="formic acid" comment="" chebi-id="CHEBI:30751" relevant="false">formic acid</ne>, <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.151" epochem-id="EPOCHEM:NEW:COMPOUND:782" name="2-propanol" comment="" chebi-id="CHEBI:17824" relevant="false">2- propanol</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.103" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>.
</P>
<P>13. Process according to claim 1, characterised in that step c) of N-Acylation takes place in the presence of an <ne type="ONT" id="WO2007045675.HC.class-names.129" epochem-id="EPOCHEM:NEW:CLASS:1066" name="aprotic organic solvent" comment="" chebi-id="WO2007045675:491390" relevant="false">aprotic organic solvent</ne> and an organic or <ne type="ONT" id="WO2007045675.HC.class-names.110" epochem-id="EPOCHEM:NEW:CLASS:550" name="inorganic base" comment="" chebi-id="WO2007045675:658098" relevant="false">inorganic base</ne>, at a temperature between -20&lt;0&gt;C and 40&lt;0&gt;C to give the compound of formula (II) .
</P>
<P>14. Process according to claim 13, characterised in that it is carried out at a temperature between -10 and
</P>
<P>5 10&lt;0&gt;C.
</P>
<P>15. Process according to claim 13, characterised in that said <ne type="ONT" id="WO2007045675.HC.class-names.130" epochem-id="EPOCHEM:NEW:CLASS:1066" name="aprotic organic solvent" comment="" chebi-id="WO2007045675:491390" relevant="false">aprotic organic solvent</ne> is chosen from <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.121" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.253" epochem-id="EPOCHEM:NEW:COMPOUND:791" name="THF" comment="" chebi-id="WO2007045675:52513" relevant="false">THF</ne>) , <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.118" epochem-id="EPOCHEM:NEW:COMPOUND:775" name="dimethoxyethane" comment="" chebi-id="WO2007045675:611049" relevant="false">dimethoxyethane</ne> (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.256" epochem-id="EPOCHEM:NEW:COMPOUND:792" name="DME" comment="" chebi-id="CHEBI:42263" relevant="false">DME</ne>) and 0 <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.124" epochem-id="EPOCHEM:NEW:COMPOUND:776" name="acetonitrile" comment="" chebi-id="CHEBI:38472" relevant="false">acetonitrile</ne> .
</P>
<P>16. Process according to claim 15, characterised in that said solvent is <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.122" epochem-id="EPOCHEM:NEW:COMPOUND:239" name="tetrahydrofuran" comment="" chebi-id="CHEBI:26911" relevant="false">tetrahydrofuran</ne> (<ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.254" epochem-id="EPOCHEM:NEW:COMPOUND:791" name="THF" comment="" chebi-id="WO2007045675:52513" relevant="false">THF</ne>) .
</P>
<P>5 17. Process according to claim 13, characterised in that said <ne type="ONT" id="WO2007045675.HC.class-names.125" epochem-id="EPOCHEM:NEW:CLASS:1064" name="organic base" comment="" chebi-id="WO2007045675:926339" relevant="false">organic base</ne> is chosen from a <ne id="WO2007045675.HC.class-names.73" epochem-id="EPOCHEM:NEW:CLASS:804" name="heterocyclic compound" comment="" chebi-id="CHEBI:5686" relevant="false" type="CLASS">heterocyclic compound</ne> that contains one or more atoms of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.266" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne>.
</P>
<P>18. Process according to claim 17, characterised 0 in that said <ne id="WO2007045675.HC.class-names.74" epochem-id="EPOCHEM:NEW:CLASS:804" name="heterocyclic compound" comment="" chebi-id="CHEBI:5686" relevant="false" type="CLASS">heterocyclic compound</ne> with at least one atom of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.267" epochem-id="EPOCHEM:NEW:COMPOUND:749" name="nitrogen" comment="" chebi-id="CHEBI:25555" relevant="false">nitrogen</ne> is chosen from <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.279" epochem-id="EPOCHEM:COMPOUND:5830" name="pyridine" comment="" chebi-id="CHEBI:16227" relevant="false">pyridine</ne> or substituted <ne id="WO2007045675.HC.class-names.131" epochem-id="EPOCHEM:NEW:CLASS:1067" name="pyridines" comment="" chebi-id="CHEBI:26421" relevant="false" type="CLASS">pyridines</ne> <ne id="WO2007045675.HC.class-names.133" epochem-id="EPOCHEM:NEW:CLASS:1068" name="collidines" comment="" chebi-id="WO2007045675:946337" relevant="false" type="CLASS">collidines</ne> or <ne id="WO2007045675.HC.class-names.4" epochem-id="EPOCHEM:NEW:CLASS:161" name="lutidines" comment="" chebi-id="WO2007045675:273306" relevant="false" type="CLASS">lutidines</ne>; or <ne id="WO2007045675.HC.class-names.39" epochem-id="EPOCHEM:NEW:CLASS:168" name="imidazole" comment="" chebi-id="CHEBI:16069" relevant="false" type="CLASS">imidazole</ne> or <ne id="WO2007045675.HC.class-names.40" epochem-id="EPOCHEM:NEW:CLASS:168" name="imidazole" comment="" chebi-id="CHEBI:16069" relevant="false" type="CLASS">imidazole</ne> substituted as <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.63" epochem-id="EPOCHEM:NEW:COMPOUND:759" name="2- methylimidazole" comment="" chebi-id="WO2007045675:164819" relevant="false">2-methylimidazole</ne> or <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.116" epochem-id="EPOCHEM:NEW:COMPOUND:774" name="4-methylimidazole" comment="" chebi-id="WO2007045675:888814" relevant="false">4- methylimidazole</ne> . 5
</P>
<P>19. Process according to claim 13, characterised in that said reaction of N-Acylation takes place in the presence of 1 or 2 equivalents of <ne type="CHEMICAL" id="WO2007045675.HC.chemical-names.114" epochem-id="EPOCHEM:COMPOUND:5421" name="water" comment="" chebi-id="CHEBI:15377" relevant="false">water</ne> in relation to the amount of starting product (VI) . 0
</P>
<P>20. Process for obtaining the synthesis intermediate of formula (II), according to claim 1, characterised in that steps a) and b) are carried out in a one-pot reaction.
</P></DIV>
<DIV><P>
</P></DIV>
</BODY>
</PAPER>
